Sound Pharmaceuticals (SPI) is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, ...

Compact, cable-free C-arm aims to maximize space and movement and allow greater flexibility and accessibility for everyday performancePatient-centric design featuring lateral wide-bore cone beam ...

Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoringMORRISVILLE, N.C.--(BUSINESS ...

Partnership with CHC in Taiwan will pilot SoluPet's flagship Neuronal Defense™ formulation through CHC's veterinary and consumer-health ecosystem TORONTO, ON / ACCESS Newswire / December 1, 2025 / ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3rd, at 10:00 a.m. ET.

Incyte (Nasdaq:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key ...

The "The EU Regulations for Digital Medical Devices with AI Components - A Basket Full of Requirements - What Does a Manufacturer Need to Consider? (Dec 9, 2025)" training has been added to ...

LAWRENCEVILLE, GA / ACCESS Newswire / December 1, 2025 / Vastian, a leading provider of Quality management software for hospitals and laboratories, will showcase its innovative solutions at the 2025 ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing ...

Merck granted Fast Track Designation by the U.S. FDA for MK-2214 for the treatment of Alzheimer's diseaseRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and ...